SCHEMBL7187747

SCHEMBL7187747

COc1cc(OC)c(C(=O)Pc2ccc(OCCC(C)C)cc2OCCC(C)C)c(OC)c1.[LiH]

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.41
KMT2A Q03164 1/20 0.40
EPHX2 P34913 1/20 0.40
MGAM O43451 1/20 0.38
GAA P10253 1/20 0.38
SI P14410 1/20 0.38
MGAM2 Q2M2H8 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
CYP3A4 P08684 2/20 0.37
USP2 O75604 1/20 0.37
TP53 P04637 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
S1PR1 P21453 1/20 0.37
S1PR5 Q9H228 1/20 0.37
HTT P42858 1/20 0.36
TDP1 Q9NUW8 2/20 0.36
LMNA P02545 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7186811 0.92 HTT (0.41) MAPK1KMT2AEPHX2MGAMGAA
SCHEMBL7183202 0.91 MAPK1 (0.40) MAPK1KMT2AEPHX2MGAMGAA
SCHEMBL7187096 0.87 THRA (0.43) MAPK1KMT2AGAASMN1; SMN2CYP3A4
SCHEMBL7181350 0.87 KMT2A (0.42) MAPK1KMT2ASMN1; SMN2CYP3A4USP2
SCHEMBL7189896 0.87 KMT2A (0.42) MAPK1KMT2ASMN1; SMN2CYP3A4USP2
SCHEMBL7177413 0.86 S1PR1 (0.38) MAPK1EPHX2MGAMGAASI
SCHEMBL7180578 0.86 KMT2A (0.41) MAPK1KMT2ASMN1; SMN2CYP3A4USP2
SCHEMBL7186646 0.86 MAPK1 (0.46) MAPK1KMT2AEPHX2MGAMGAA
SCHEMBL7179779 0.85 THRA (0.47) KMT2AGAA
SCHEMBL7183640 0.85 MAPK1 (0.38) MAPK1KMT2AEPHX2MGAMGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MAPK1 1801/4885KMT2A 1586/4885EPHX2 2476/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MAPK1 2710/4885KMT2A 956/4885EPHX2 2048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.